Prostate Cancer, Version 1.2014
James L. Mohler, Maria Ho, Michael B. Cohen(Albany Medical Center Hospital), Elizabeth R. Plimack(Fox Chase Cancer Center), Eric Rohren(Society of Nuclear Medicine and Molecular Imaging), Andrew J. Armstrong(Duke University), Richard J. Lee(La Roche College), Jonathan D. Tward(University of Utah), Julio M. Pow‐Sang(Moffitt Cancer Center), Sylvia Richey(St. Jude Children's Research Hospital), Seth A. Strope(Barnes-Jewish Hospital), Eric M. Horwitz(Fox Chase Cancer Center), Philip W. Kantoff(Convergent Science (United States)), Gary R. MacVicar(Northwestern University), Anthony V. D’Amico(Brigham and Women's Hospital), Dorothy A. Shead(University of the Witwatersrand), Stan Rosenfeld(Office of Patient Care Services), Mack Roach(University of California, San Francisco), David C. Miller(University of Michigan), Thomas A. Farrington(Health Net), Sandy Srinivas(Stanford University), Arnold W. Malcolm(Vanderbilt University), Cy A. Stein(City Of Hope National Medical Center), Charles A. Enke(Susan Thompson Buffett Foundation), Patrick C. Walsh(Johns Hopkins University), Robert R. Bahnson(Fox Chase Cancer Center), Michael Kuettel, Mark H. Kawachi(City of Hope), Celestia S. Higano(University of British Columbia), James A. Eastham(Memorial Sloan Kettering Cancer Center), Eric J. Small(CancerCare Manitoba)
Cited by 132
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k